Introduction
============

Histone deacetylase (HDAC) 2 plays a crucial role in modifying histones to regulate the expression of inflammatory genes ([@B4], [@B5]; [@B15]). Our previous studies have shown that carbocisteine (S-CMC), an anti-oxidant agent extensively used as adjunctive therapy in the treatment of chronic obstructive pulmonary disease (COPD), could reverse the down-regulation of HDAC2 induced by oxidative stress and enhance the sensitivity of human alveolar epithelial cells to glucocorticoid (GC) treatment ([@B25]). However, it remains to be understood regarding the mechanism by which S-CMC ameliorates HDAC2 expression and/or activity.

Protein expression/activity is largely dependent on epigenetic modulations or post-translational modification (PTM) such as phosphorylation, nitrosylation, ubiquitination and sumoylation. PTM indicates that the proteins encoded by genes are further modified by a series of enzymatic reactions, resulting in the specific chemical modification of the amino acid residues on the protein peptide chain, which usually involves chemical modifications of proteins via linkage of chemical groups, lipids, sugars or polypeptides with the proteins ([@B12]; [@B30]). As a result, these chemical modifications cause a variety of structural and functional alteration that mediate biological and/or pathological process ([@B3]; [@B20]; [@B24]; [@B30]; [@B17]).

HDAC2, as a regulating protein of histone acetylation, is also modified by post-translational regulation ([@B7]; [@B24]; [@B11]). Studies have shown that HDAC2 expression/activity inhibited by oxidative stress is closely associated with the epigenetic modifications, such as phosphorylation ([@B1]), nitrosylation ([@B22]; [@B23]; [@B19]), ubiquitination ([@B1]) and so on. SUMO, as an important PTM factor, is involved in the regulation of HDAC2 ([@B8]; [@B29]).

SUMO, a small ubiquitin-like modifier, is widely expressed in eukaryotic cells and is composed of highly conserved four family members, including SUMO1, SUMO2, SUMO3, and SUMO4. SUMO covalently binds to a lysine residue of substrates. Sumoylaton is a dynamic reversible process and occurs under physiological or pathological condition ([@B16]; [@B12]). It plays an important role in regulating the function and stability of proteins ([@B16]; [@B18]). For example, sumoylation of HDAC2 promotes NF-KappaB-dependent gene expression ([@B29]). Sumoylation of HDAC2 at lysine 462 permits HDAC2 binding to p53, which in turn blocks the recruitment of p53 into the promoter regions of targeted genes that mediates cell cycle and cell apoptosis ([@B8]). Protein sumoylation is sensitive to diverse cellular stresses, and oxidative stress not only directly modifies proteins but also lead to indirect changes in SUMO modifications that regulate protein functions ([@B6]). However, the relationships between oxidative stress induced by cigarette and SUMO modification of HDAC2 has not been reported so far, which may further reveal the mechanism of S-CMC to regulate HDAC2.

In this study, we aimed to investigate the effects of S-CMC on cigarette smoke extract (CSE)-induced HDAC2 SUMOylation and the subsequentinflammatory responses. We first determined the SUMO modification of HDAC2 under a physiological condition, and explored the effects of oxidative stress induced by cigarette on HDAC2 sumoylation. Next, we determined the specific modification site of HDAC2 and revealed the effects of SUMO modification on the biological function of HDAC2. Finally, we investigated the effects and mechanisms of thiol antioxidant S-CMC on the HDAC2 sumoylation, to provide new targets for the treatment of steroid-resistant COPD.

Materials and Methods {#s1}
=====================

Cell Culture and Treatments
---------------------------

The human tracheobronchial epithelial (16HBE) cell line \[obtained from the American Type Culture Collection (Manassas, VA, United States)\] was maintained in DMEM medium supplemented with 10% fetal bovine serum, L-glutamine (2 mM), penicillin (100 U/mL), and streptomycin (100 U/mL). Unless otherwise stated, cell culture reagents were purchased from Gibco (United States). CSE was prepared as previously reported ([@B25]). Briefly, CSE was prepared by the combustion of one cigarette (12 mg tar/cigarette; Double Happiness, China), using a pump and passing the smoke through 10 mL of non-FBS culture medium at a rate of 5 min/cigarette. The resulting solution was adjusted to pH 7.4 with 1.0 M NaOH and strained through 0.22 μm gauge filters. The obtained solution represented 100% strength and was diluted to the desired concentration with culture medium. The fresh CSE was used within 30 min.

Cells were pre-incubated with or without S-CMC (Sigma-Aldrich, United States) and buthioninesulfoximine (BSO; Sigma-Aldrich, United States) for 1 h and then exposed to CSE. These treatments showed no significant cytotoxic effects as measured with a cck-8 counting kit (Dojindo, Japan) and trypan blue exclusion method.

Immunoprecipitation
-------------------

16HBE cells were plated in 10 cm cell culture dish, washed with ice-cold PBS and scraped the dish with 600 μL ice-cold lysis-buffer (20 mM Tris-HCl pH 7.4, 150 mM NaCl, 10%glycerol, 0.3%Triton X-100, 0.5%NP-40, 4 mM EDTA) supplemented with 1mM NaVO3, 1mM PMSF, 20mM N-Ethylmaleimide (Sigma, prepared fresh) and Complete protease inhibitor cocktail (Roche, 1:100) and pipetted into 1.5 mL Eppendorf tubes. Cells were incubated on ice for 30 min and sonicated in an ice water bath (amplitude 20%, 3 × 5 s), then centrifuge 14,000 g for 5 min at 4°C, gently transfer the supernatant to a new tube. BCA kit was used to measure the total protein of each tube, and the total protein concentration of each tube was adjusted to the same level with IP lysate. Two hundred micro liter l lysates were enriched by adding anti-HDAC2 or SUMO antibodies (1--2 μg) overnight at 4°C, then added 20 μL pre-cleared Protein A/G-agarose (CST) for 6 h. Complexes were centrifuged at 13,000 × g at 4°C for 30 s. The pellet were washed 5 times with lysis buffer and resuspended in 30 μL 2 × loading buffer (+100:1 PMSF) and heated to 100°C for 5 min. The samples were centrifuged at 2000 rpm, and the supernatant was subjected to protein separation by 10% SDS-PAGE. Western blot analysis was performed as described below.

Western Blot
------------

For the analysis of proteins expression, the 16HBE cells lysate was prepared by RIPA Lysis Buffer (+PMSF, 100:1; Beyotime Institute of Biotechnology, China). The total protein was extracted by centrifugation (14,000 × *g*, 4°C, 10 min) in the supernatant for gel electrophoresis. After western transfer, PVDF membranes were probed with mouse anti-HDAC2 antibody, followed by horseradish peroxidase-conjugated anti-mouse (1:5000) antiserum (Santa Cruz Biotech, United States). Protein bands were visualized using SuperSignal (Pierce). The membranes were lastly re-probed with an anti-IgG antibody (Signalway Antibody, United States) as loading controls. The quantitiy of loading samples were adjusted to ensure the same contents of HDAC2 in each group according to the initial result detected by IP-WB.

Immunofluorescence
------------------

Cells were grown on chamber slides and treated as designed. After intermediate washes with cold phosphate buffered saline (PBS), cells were fixed with 4.0% paraformaldehyde in PBS for 15 min at RT. The cells were rinsed in cold PBS and blocked in 5% bovine serum albumin for 1 h at RT. Cells were then incubated with primary antibodies, HDAC2 (1:200 dilution; CST), SUMO1 (1:200 dilution, CST) and SUMO2/3 (1:200 dilution, CST) overnight at 4°C, washed with cold PBS, incubated with Alexa Fluor-conjugated secondary antibodies at RT for 1 h, washed with PBS again, and then stained with 1 μg/mL (w/v) 4,6-diamidino-2-phenylindole (DAPI) for 5 min at RT. After washing, images were collected using an Axioscope microscope system (Leica, Germany) at 40× magnifications.

High Content Screening (HCS) Assay
----------------------------------

HDAC2 expression in 16HBE cells were measured by HCS technology based on immunocytofluorescence. Anti-HDAC2 primary antibody (mouse anti-human; Cell Signaling Technology, United States) was incubated overnight, followed by incubation with secondary antibodies (DyLight 555 nm, goat anti-mouse; Cell Signaling Technology, United States) for 60 min in the dark and stained with 4,6-diamidino-2-phenylindole (DAPI, Sigma-Aldrich, United States). Fluorescence was detected using a HCS Reader (Thermo Fisher Scientific, United States) at 10× magnifications to quantify HDAC2 expression.

Short Hairpin RNA (shRNA) Interference
--------------------------------------

HDAC2 site-specific mutagenesis was performed by transfecting 16HBE cells with HDAC2 shRNA (Shanghai Gima Co., Ltd., China) according to the manufacturer's instructions. 16HBE cells grown to 30--50% confluency were transfected by lentiviral-delivered shRNA (multiplicity of infection = 20), strengthened by polybrene (5 g/mL) for 24 h. Then, the medium was replaced with fresh medium without shRNA and polybrene, and the culture was incubated for another 48 h. The infection efficiency was ≥ 50% according to green fluorescent protein analysis. Cells then were screened with puromycin (2.5 g/mL) for 3--5 days and monoclonal cells were maintained for further experimentation.

Chromatin Immunoprecipitation (ChIP)- PCR Assays
------------------------------------------------

The ChIP assay was performed using the SimpleChip Enzymatic Chromatin IP kit (Cell Signaling Technology, United States) following the manufacturer's instructions. The eluted DNA was checked for 100--300 bp fragment enrichment by 8% polyacrylamide gelelectrophoresis. The immunoprecipitated DNA was used amplified using specific gene (IL-8 for humans) promoter qPCR assays. The following PCR primer sequences were used for the IL-8 promoter: forward, 5′-GGGTGCATAAGTTCTCTAG-3′ (position: 3-21) and reverse, 5′-TTCCTTCCGGTGGTTTCTTC-3′ (position: 114-133).

Statistical Analysis
--------------------

Quantitative data are presented as means ± standard error of the mean (SEM). Statistical analysis was performed using a one-way analysis of variance followed by the Dunnett's test for multiple comparisons. All analyses were performed using Prism GraphPad5.0 statistical software. A probability (*p*) value \< 0.05 was considered statistically significant.

Results
=======

HDAC2 Is Covalently Modified by SUMO1 and SUMO2/3 Under Physiological Condition
-------------------------------------------------------------------------------

First, we explored the interaction between HDAC2 and SUMO1 or SUMO2/3 under a physiological condition using immunoprecipitation and immunofluorescent staining. Cell lysates of normal 16HBE cells were subjected to immunoprecipitation using an antibody against HDAC2, followed by western blotting using an antibody against SUMO1. Results exhibited that there was a single ∼100 kD and detected by SUMO1 antibody without free SUMO1 band (∼11 kD), indicating the possible covalent binding of HDAC2 and SUMO1 ([Figure 1A](#F1){ref-type="fig"}). Moreover, the same band at ∼100 kD was observed by reverse immunoprecipitation experiment ([Figure 1B](#F1){ref-type="fig"}), suggesting that HDAC2 is covalently modified by SUMO1 under a physiological condition. Then, the similar IP and IB experiment was used to confirm the interaction between HDAC2 and SUMO2/3. Interestingly, we found only a free SUMO2/3 band (∼11 kD), with no any band that represented the complex of HDAC2 and SUMO2/3 ([Figure 1C,D](#F1){ref-type="fig"}), suggesting the non-covalent interaction may occur between SUMO2/3 and HDAC2.

![The interaction and colocalization of HDAC2 and SUMO1 or SUMO2/3 in 16HBE cells under physiological condition by immunoprecipitation and confocal microscopy. **(A,C)** Cell lysates were subjected to immunoprecipation using anti-HDAC2 antibodies. SUMOylated HDAC2 was detected by Western blot using anti-SUMO1 or SUMO2/3 antibodies. Lane 1: input (whole cell lysate without IP treatment); Lane 2: immunoprecipitation with IgG (H + L chains) but without HDAC2 antibody; Lane 3: normal IP. **(B,D)** Cell lysates were subjected to immunoprecipation using anti-SUMO1 or SUMO2/3 antibodies. SUMOylated HDAC2 was detected by Western blot using anti-HDAC2 antibodies. Lane 1: immunoprecipitation with IgG (H + L chains) but without SUMO1 or SUMO2/3 antibody; Lane 2: normal IP **(E)** Representative confocal images of fluorescently labeled nucleus (blue, channel 1: 386 nm), SUMO1 or SUMO2/3 (green, channel 2: 488 nm) and HDAC2 (red, channel 3: 555 nm) in 16HBE cells in physiological conditions. There is a colocalization of HDAC2 and SUMOs in nucleus of 16HBE cells (Merge1+2+3).](fphar-10-00166-g001){#F1}

Next, we sought to visualize if HDAC2 and SUMO1, 2, 3 are co-localized in the nucleus. Immunofluorescent staining showed the colocalization of HDAC2 with SUMO1 or SUMO2/3 in the nuclei of 16HBE cells ([Figure 1E](#F1){ref-type="fig"}). Overlap of HDAC2 with SUMO1 or SUMO2/3 calculated by Image Pro Plus was 86 and 83%, respectively, which also suggested that there might be interaction between HDAC2 and SUMO1 or SUMO2/3 under physiological condition.

Effects of Cigarette Smoke Extract (CSE) on the Interaction Between HDAC2 and SUMO1
-----------------------------------------------------------------------------------

To evaluate if oxidative stress can influence the interaction of HDAC2 with SUMO1 or SUMO2/3, cells were treated with CSE. The immunoprecipitation analysis revealed that the interaction of HDAC2 with SUMO1 was enhanced by CSE in a dose-dependent manner compared to control group and significant difference was found at the concentration of 5% or 10% CSE ([Figure 2A](#F2){ref-type="fig"}). However, no effects of CSE on HDAC2-SUMO2/3 were observed ([Figure 2B](#F2){ref-type="fig"}). Consistent with the results of immunoprecipitation analysis, HCS analysis demonstrated that both 5 and 10% CSE treatment resulted in a significant increase in the interaction between HDAC2 and SUMO1 ([Figure 2C](#F2){ref-type="fig"}), but did not affect the interaction of HDAC2 with SUMO2/3 ([Figure 2D](#F2){ref-type="fig"}). The time course study also showed that exposure of the cells with CSE increased HDAC2-SUMO1 interaction during 0.25--0.5 h ([Figure 2E](#F2){ref-type="fig"}). As expected, the similar results were obtained using the HCS analysis ([Figure 2G](#F2){ref-type="fig"}). The interaction between HDAC2 and SUMO2/3 was, however, not influenced by CSE ([Figure 2F,H](#F2){ref-type="fig"}). These data indicate that CSE induces association between HDAC2 and SUMO1 in a dose- and time-dependent fashion.

![The effects of CSE in different concentrations and different incubation time on HDAC2 and SUMO1 or SUMO2/3 interaction in 16HBE by immunoprecipitation and HCS analysis. **(A,B)** Effects of treatment with CSE under 0, 1, 2.5, 5, and 10% concentrations for 30 min in SUMOylated HDAC2 in 16HBE cells by immunoprecipitation. **(C,D)** Effects of treatment with CSE under 0, 1, 2.5, 5, and 10% concentrations for 30 min in SUMOylated HDAC2 in 16HBE cells by HCS analysis. **(E,F)** Effects of treatment with CSE for 0, 15, 30 min, 1 and 2 h in SUMOylated HDAC2 in 16HBE cells by immunoprecipitation. **(G,H)** Effects of treatment with CSE for 0, 15, 30 min, 1 and 2 h in SUMOylated HDAC2 in 16HBE cells by HCS analysis. Data are expressed as the means ± SEM, *n* = 6. Ns means no significant difference and ^∗∗^*p* \< 0.01 and ^∗∗∗^*p* \< 0.001 compared to control group (0% CSE or 0 h) using one-way ANOVA with Dunnett *t*-test for selected pairs.](fphar-10-00166-g002){#F2}

K51 and K462 Are HDAC2 Modification Sites
-----------------------------------------

As is known to us, the molecular weight of SUMO is about 11 kD, but SUMOs appear larger on SDS-PAGE and add ∼20 kD to the apparent molecular weight of most substrates ([@B16]). Based on the founding of the molecular weight of HDAC2-SUMO1 complex, we speculated that there are two SUMO1 proteins covalently attached on the HDAC2. Since SUMO-1 is thought not to form dimer or polymers as well as SUMO2/3 ([@B26]), we speculated that there are two different sites of HDAC2 for SUMO1 modification. A few of lysine residues in the sequence of HDAC2 are predicted as the potential sumoylation sites of HDAC2 by three softwares (SUMOplot, SUMOsp2.0, and seeSUMO) based on different prediction algorithm. Results showed that lysine residues K462, K51, K145, and K451 might be the most potential sumoylation sites of HDAC2.

To identify the sumoylation sites of HDAC2, 16HBE cells were transfected with HDAC2-K462R, HDAC2-K51R, HDAC2-K145R, and HDAC2-K451R using lentivirus vector for site-directed mutagenesis. Cells lysates were subjected to immunoprecipitation using HDAC2 antibody. We found that K462R and K51R mutations resulted in the changes of sumoylated HDAC2-SUMO1 complex from 100 to 80 kD, while K145R and K451R mutations did not affect the sumoylation ([Figure 3](#F3){ref-type="fig"}). Therefore, K462 and K51 sites were identified as the possibly primary HDAC2 sumoylation sites.

![Identification of K51 and K462 as the HDAC2 SUMOylation sites. 16HBE cells were transfected with HDAC2-K462R, HDAC2-K51R, HDAC2-K145R, HDAC2-K451R using lentivirus vector. Cells lysates were subjected to immunoprecipitation using HDAC2 antibody. SUMOylated HDAC2 was detected by Western blot using anti-SUMO1 antibody.](fphar-10-00166-g003){#F3}

Biological Function of SUMO1 Modification of HDAC2
--------------------------------------------------

Since CSE can induce HDAC2 sumoylation, we reasoned that increased HDAC2 sumoylation leads to suppression of histone deacetylation, while sumoylation-mutated HDAC2 increases deacetylation of histone. To test this hypothesis, we found that 5% CSE significantly increased the acetylation level of histone H4 in wild-type 16HBE cells ([Figure 4A](#F4){ref-type="fig"}), decreased HDAC2 activity ([Figure 4B](#F4){ref-type="fig"}) and increased IL-8 promoter acetylation ([Figure 4C](#F4){ref-type="fig"}) compared with control group by using chromatin immunoprecipitation and HDAC activity assay kit. Compared with the wild type 16HBE cells, K51 mutation resulted in decreased histone H4 acetylation, increased HDAC2 activity and decreased IL-8 acetylation while K462R mutation had no influence in the presence of CSE. These results suggest that CSE enhances SUMO1 modification of HDAC2 at K51 and then regulates histone and IL-8 promoter acetylation.

![The biological function of SUMO1 modification of HDAC2. **(A)** HDAC2 binding and histone acetylation were analyzed by ChIP analysis in 16HBE wild type, 16HBE-K51R and 16HBE-K462R cells after CSE incubation for 0.5 h. **(B)** HDAC activity in 16HBE wild type, 16HBE-K51R and 16HBE-K462R cells after CSE incubation for 0.5 h. **(C)** histone acetylation of the IL-8 gene promoter in 16HBE wild type, 16HBE-K51R and 16HBE-K462R cells after CSE incubation for 0.5 h. Data are presented as means ± SEM (*n* = 6). Ns means no significant difference and ^∗∗^*p* \< 0.01 compared to wild type using one-way ANOVA with Dunnett *t*-test for selected pairs.](fphar-10-00166-g004){#F4}

S-CMC Reversed the Effects of CSE on HDAC2-SUMO1 Interaction, HDAC Activity and IL-8 Release
--------------------------------------------------------------------------------------------

To investigate whether S-CMC can reverse the effects of CSE on HDAC2-SUMO1 interaction, immunoprecipitation was performed ([Figure 5A](#F5){ref-type="fig"}). It was found that S-CMC could inhibit the CSE-induced SUMO1 modification of HDAC2 in a dose-dependent manner (10^−6^--10^−4^ M). At the same time, other thiol donor drugs (NAC, GSH, GSH mimetics, at the 10^−4^ M) showed similar effects compared with S-CMC (10^−4^ M) ([Figure 5A](#F5){ref-type="fig"}). However, the effect of S-CMC was significantly reversed by the addition of buthioninesulfoximine (BSO), a specific inhibitor of GSH synthesis ([Figure 5A](#F5){ref-type="fig"}). Simultaneously, we also found S-CMC could reverse CSE- induced decrease of HDAC activity ([Figure 5B](#F5){ref-type="fig"}) and increased of IL-8 levels ([Figure 5C](#F5){ref-type="fig"}) in a dose-dependent manner. Other thiol donors (10^−4^ M) also showed similar effects, which was also blocked by the addition of BSO.

![S-CMC reversed the effects of CSE on HDAC2-SUMO1 interaction, HDAC activity and IL-8 release. 16HBE cells were pre-incubated with S-CMC (10^−6^--10^−4^ M) or NAC, GSH, GSH mimetics (10^−4^ M) with or withnot BSO (10^−4^ M) for 1 h, following 5% CSE incubation for 30 min **(A)** Analysis for interaction between HDAC2 and SUMO1 by immunoprecipitation. **(B)** The activity of HDAC in 16HBE cells was detected using a HDAC activity assay kit. **(C)** Level of IL-8 in the indicated groups were measured by ELISA. Data are expressed as the means ± SEM, *n* = 6. ^\#\#^*p* \< 0.01 and ^\#\#\#^*p* \< 0.001 compared to control group using unpaired *t*-test. Ns means no significant difference, ^∗^*p* \< 0.05, ^∗∗^*p* \< 0.01, and ^∗∗∗^*p* \< 0.001 compared to CSE group using one-way ANOVA with Dunnett *t*-test for selected pairs. ^†††^*p* \< 0.001 compared to the CSE+S-CMC (10^−4^ M) treatment group using unpaired *t*-test.](fphar-10-00166-g005){#F5}

Discussion
==========

Recent studies have revealed that SUMO modification plays an important role in the functional regulation of multiple proteins, such as androgen receptor ([@B2]), NF-kB pathway ([@B14]), p53 ([@B8]), and HDAC ([@B10]; [@B9]; [@B29]). SUMO modification usually occurs on the ΨKXE sequence of the target protein ([@B16]). At present, SUMOsp2.0, seeSUMO and SUMOplot are mainly used to predict the SUMO-modified sites ([@B27]). Among these predictive softwares, SUMOsp2.0 shows a better recognition of the amino acid sequences of non-ΨKXE sequences ([@B31]), SeeSUMO software mainly emphasis on the published literature for the prediction of the site ([@B21]), while SUMOplot matches up the amino acid sequence to predict possible SUMO sites ([@B32]). Therefore, in order to enhance the reliability of the predictive results, we used all three software programs to predict the SUMO modification site of HDAC2, and combined the three-dimensional structure of the protein to exclude the effects of steric hindrance. As a result, the K462, K51, K145, and K451 amino acid sites of HDAC2 were identified as the potential SUMO modification sites. Our study showed that mutation of K462 and K51, rather than K145 and K451, decreased SUMO1 modification of HDAC2. Therefore, K462 and K51 serve as SUMO1 modification sites of HDAC2. It is noteworthy that K51 is located in the enzyme domain (9--322) of HDAC2, and K462 is located outside this domain. Consistent with our results, other experimental evidence has also demonstrated that K462 site of HDAC2 is a SUMO1 modification site. Interestingly, there are also reports indicating that K462 and K481 site were identified as SUMO2/3 modification sites ([@B28]). In our study, it remains to be determined whether K462 is also a modification site for SUMO2/3.

Furthermore, the biological function of SUMO1 modification of HDAC2 at the K51 or K462 sites was also investigated by chromatin immunoprecipitation. Our study showed that K51 site mediated the deacetylation of histones and regulated the transcription of the inflammatory factor, such as IL-8. In contrast to K51, K462 site mutation failed to block HDAC2 function of histone deacetylation. As a result, we speculated that the SUMO1 modification of K462 site might be associated with other protein function. As previously study reported by Brandl et al. showed that SUMO1 modification at the K462 site of HDAC2 mediated the deacetylation of p53 protein, leading to the inhibition of p53 function ([@B8]).

Oxidative stress-induced epigenetic modification of HDAC results in the reduction of HDAC2 expression or activity. For example, cigarette smoke can cause phosphorylation of serine residues at 394, 411, and 422, thereby reducing HDAC2 expression and activity ([@B1]). Likewise, oxidative stress induces nitrosylation of tyrosine residue at 253, promoting protease-mediated degradation of HDAC2 ([@B23]). Moreover, NO mediates nitrification of cysteine residues at 262 and 274, leading to increases in the transcription of neurotrophic factors-related genes ([@B22]). In line with these evidence, we found that CSE stimulated HDAC2 modification by SUMO1, not SUMO2/3 in the nucleus, and inhibited HDAC2 activity.

Our previous study has found that oxidative stress induced higher levels of IL-8 and TNF-α ([@B25]), which resisted steroid therapy in COPD. The failure of steroid therapy was improved by the addition of S-CMC in the presence of thiol/GSH ([@B25]). Consistent with these data, we found that S-CMC inhibited CSE-induced SUMO1 modification of HDAC2in a dose-dependent manner, but BSO reversed the inhibitory effects, highlighting that S-CMC-induced HDAC2 activity is dependent on thiol/GSH. Interestingly, other thiol donor drugs had similar effects compared with S-CMC, indicating that thiol donor drugs had the regulatory effect on CSE-induced HDAC2 SUMOylation. Indeed, S-CMC, a cysteine derivative, was reported to enhance the thiol/GSH secretion from human respiratory cells ([@B13]). Recent studies also confirmed that the presence of thiol/GSH could reverse the deacetylase activity of HDAC2 ([@B19]). Moreover, our previous study revealed that increased thiol/GSH levels by S-CMC were favorable for restoring HDAC2 activity ([@B25]), supporting that thiol/GSH plays a crucial role in reduced SUMO1 modification of HDAC2. Therefore, in consistent with earlier evidence, our studies have provided the molecular mechanisms by which S-CMC blocks CSE-mediated SUMO1 modification of HDAC2 and increases HDAC2 activity in a thiol/GSH-dependent manner. Consequently, HDAC2 induces histone and IL-8 promoter deacetylation and inhibits the expression of IL-8.

Conclusion
==========

In conclusion, our results show that HDAC2 interacts with SUMO1 under physiological conditions. SUMO1 modification sites of HDAC2 are the K51 and K462 sites, and the SUMO1 modification of the K51 site plays an important role in the deacetylation function of HDAC2. Oxidative stress induced by CSE enhances the SUMO modification of HDAC2. S-CMC or other thiol donor drug treatment can attenuate the CSE- triggered SUMO modification of HDAC2 in thiol/GSH-dependent manner, which provides a mechanistic explanation for the reversal of glucocorticoid resistance by S-CMC in COPD.
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